Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05812781 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome
A Phase 2 study, sponsored by Zomagen Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT05812781: Completed Phase 2 study, sponsored by Zomagen Biosciences.
NCT05812781 is a Phase 2 study that has completed, run by Zomagen Biosciences. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05812781, a Phase 2 study, has completed, sponsored by Zomagen Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Cryopyrin-Associated Period Syndrome (CAPS). Approximately 10 patients will take VTX2735 Dose A or VTX2735 Dose B. The study consists of a screening/washout period of up to 28 weeks, a 2 week treatment period, a treatment withdrawal period of up to 2 weeks, another 2 week treatment period, and a 4 week follow up period. The maximum length of treatment is 4 weeks.
Primary Outcome
Incidence and severity of treatment-emergent adverse events (TEAE), serious adverse events (SAE), and discontinuation due to adverse events
Interventions
- DRUG VTX2735
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-03-18 |
| Est. Completion | 2024-03-06 |
| Phase | Phase 2 |
What the finished NCT05812781 record still lists
NCT05812781 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which VTX2735 is the first listed.
NCT05812781 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05812781 about?
NCT05812781 is a clinical study titled "A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome". This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Cryopyrin-Associated Period Syndrome (CAPS). Approximately 10 patients will take VTX2735 Dose A or VTX2735 Dose B. The study consists of a screening/washout period of up to 28 weeks, a 2 week treatm...
What is the current status of trial NCT05812781?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2023-03-18. Estimated completion is 2024-03-06.
What interventions are being tested in trial NCT05812781?
The interventions under investigation include: VTX2735 (DRUG).
Who is sponsoring clinical trial NCT05812781?
This trial is sponsored by Zomagen Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05812781's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI